Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Chuikyo Reps in Face-Off over Medical Fees to Address Drug Supply Disruptions
December 22, 2022
- Japan to Cut 310 Billion Yen in Drug Spending in FY2023 Off-Year Revision: Ministers
December 22, 2022
- Special PMP Increase to Offset 95% of Price Cuts for 150 Products: FY2023 Revision
December 22, 2022
- Japan Designates Antibiotics as Key Resources for Economic Security
December 21, 2022
- LDP Health Panel OKs FY2023 Budget Plan; MHLW Gives “Low 300-Billion-Yen Range” for Drug Cost Cut
December 20, 2022
- Still No Serious Safety Concerns with COVID-19 Vaccines: MHLW Panels
December 20, 2022
- LDP Lawmakers Give Certain Credit to FY2023 Price Revision Plan
December 20, 2022
- Susmed’s Insomnia App in Line for Approval as Early as January
December 20, 2022
- Healthcare Providers Rap Product Coverage of Off-Year Re-Pricing, Payers Hail Threshold: Chuikyo
December 19, 2022
- Orphan Drug Tag Granted for Takeda’s Maralixibat and More
December 19, 2022
- Ruling Parties OK FY2023 Tax Reform Outline; No More Special COVID Measure for R&D Credits
December 19, 2022
- Chuikyo OKs FY2023 Price Revision Outline Specifying “0.625 Times” Product Coverage Threshold
December 19, 2022
- Ministers Agree on “4.375%” Product Coverage Line for 2023 “Off-Year” Drug Price Revision
December 16, 2022
- Off-Year Re-Pricing Expected to Cover 70% of Listed Products; Special Steps for Unprofitable Drugs, Patented Meds
December 16, 2022
- Insmed’s Arikayce Braces for Price Cuts under CEA Scheme
December 15, 2022
- Finance Minister Hears Out LDP Group’s Emergency Proposal on Off-Year Re-Pricing
December 14, 2022
- Japan to Refit R&D Tax Credit System to Boost Incentive; Lower Minimum Deduction Rate, Variable Cap
December 14, 2022
- Japan to Add Age 12-17 for Moderna Boosters in Free Emergency Program
December 14, 2022
- Japan Govt to Purchase Another 1 Million Courses of Xocova
December 14, 2022
- LDP Committee Insists on Better Handling of Innovative Drugs, Unprofitable Meds in Off-Year Re-Pricing
December 13, 2022
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…